A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons.

Trial Profile

A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2013

At a glance

  • Drugs Valaciclovir (Primary) ; Aciclovir
  • Indications Herpes simplex virus type 2 infections; HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2012 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top